Skip to main content
Fig. 3 | Journal of Pharmaceutical Policy and Practice

Fig. 3

From: Cost-effectiveness analysis of current non-mandatory hepatitis B vaccination coverage vs expanding coverage among healthcare workers in Ethiopia

Fig. 3

Tornado diagram of current hepatitis coverage vs increasing current hepatitis coverage. ICER: incremental cost-effectiveness ratio; P_dieSeq: probability of die due to sequale; P_dieinfe: probability of die due to Hepatitis B virus infection; P_ChroniHBV: probability of chronic hepatitis B virus progression; P_untreatsquale: probability of untreated HCWs with sequale; C_labinve: cost of lab investigation; C_hosp: cost of hospitalization; P_treatchrohepa: probability of treated HCWs with chronic hepatitis; C_txt: cost of CHB treatment with tenofovir and optionally with diuretics as a prophylaxis for squelae; P_dieoth: probability of die due to other causes; P_infectunvacc: probability of infection in unvaccinated HCWs; P_current: probability of current vaccine coverage; E_vacc: effectiveness of Vaccine; P_immun: probability of developing immunity; P_Sucsep: probability of susceptibility; P_sequelae: probability of progressing to sequelae; P_deathacuhep: probability of death due to acute hepatitis

Back to article page